Pharming Group nominates Dr. Richard Peters for election to its Board as Non-Executive Director and Chairman-designate

– NETHERLANDS, Leiden –  Pharming Group N.V. (AMS: PHARM | Nasdaq: PHAR) today announced the nomination of Dr. Richard Peters (MD, PhD) for his appointment to its Board as Non-Executive Director and Chairman designate, at an upcoming Extraordinary GM.

“The Board is pleased to nominate Dr. Richard Peters as the new Chairman of the Board of Directors. Dr. Peters is a highly respected and proven industry leader, who brings extensive medical and commercial acumen for difficult-to-treat and rare diseases, from the development stage to large global biopharmaceutical companies. I am delighted that Dr. Peters will become my successor following his appointment by the general meeting.” said current Board chairman, Paul Sekhri.

About Dr. Richard Peters

Dr. Richard Peters (Belgian national, US citizen) has over 30 years of experience in the healthcare industry and academia. He currently serves as Non-Executive Director for Kineta (NASDAQ: KA) and Aprea Therapeutics (NASDAQ: APRE), and is the founder and Executive Chairman of TellBio. He is also a corporate advisor to Aura Biosciences.

Before these roles, Dr. Peters served as the Global Head of the Rare Diseases business at Sanofi Genzyme, and CEO of two Nasdaq-listed biotechnology companies: Yumanity Therapeutics and Merrimack Pharmaceuticals. Earlier in his career, Dr. Peters held medical leadership positions at Amgen, Onyx Pharmaceuticals, Genzyme, and Sanofi, and is a founder of X4 Therapeutics (NASDAQ: XFOR) and PIC Therapeutics. He has also served on the Massachusetts General Hospital faculty, as an editor for the journals SCIENCE and JAMA, and has published over 100 editorial and research articles.

Dr. Richard Peters said: “I am honored to have been nominated to become the new Chairman of the Board of Directors of Pharming, as successor to Mr. Paul Sekhri. I look forward to working together with the members of the Board of Directors and the Executive Committee in helping propel Pharming to achieve its long-term strategic objectives, guided by Pharming’s clear vision and mission to become the rare disease company of choice to serve the unserved rare disease patient.”

He completed Internal Medicine training at the Massachusetts General Hospital and a Howard Hughes post-doctoral fellowship at Harvard Medical School; both in Boston, MA. Dr. Peters holds an M.D. Degree and a PhD. in Pharmacology from the Medical University of South Carolina, Charleston, South Carolina, and began his medical studies at the Universite Catholique de Louvain in Belgium before immigrating to the US.

About Pharming Group N.V.

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming patients’ lives with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.